Toxicovigilance of Novel Synthetic Substances using Social Media and Forum Data (1 CME)
(1 CME) In this conference recording from the 2019 Annual Conference, you will learn:
|Novel psychoactive substances (NPS) is defined in toxicological and addiction literature as the class of substances which have been either newly synthesized or involve pre- existing substances that are abused in novel ways. NPS have become increasingly abused in the United States in part due to their ease of access, availability on the internet, higher potency or longer duration of effect, and sometimes a loophole bypassing the laws of scheduled drugs. By 2015, over 700 such substances have been reported internationally. Of the subclasses, synthetic cathinones, synthetic cannabinoids and psychedelics/phenethylamines account for the largest portion of NPS reports. These drugs are often abused recreationally or as a means of “self-medicating” in order to moderate and/or potentiate the side effects of other drugs, or to treat symptoms such as anxiety and agitation. Because there is great variability in the effects, formulations, and potencies of these compounds, they have potential to cause significant morbidity and mortality. NPS are rapidly being developed and cleverly introduced into society in order to avoid legal implications. The literature detailing the effects and usages of these substances is scarce. As a result, providers rely on their prior experiences with “similar” medications in order to hypothesize how a NPS will effect someone. However, this has significant limitations. In order to respond to the rise of abuse and decrease complications, the medical community needs a better understanding of NPS. In an effort to better understand these substances and evaluate trends, our research group analyzed online forum discussions of users whom described personal experiences with a substance. We then performed a thematic analysis to characterize the study sample.|
|1.) Better understand Novel Psychoactive Substances (NPS) by learning about their origin, prevalence, and legal controversies.|
|2.) Treat acute overdose, abuse, and complications of Novel Psychoactive Substances more comfortably.|
|3.) Locate resources that will provide information about specific novel psychoactive substances in order to provide more comprehensive care for your patients.|
|Vincent Ceretto DO, MA graduated Summa Cum Laude from SUNY University at Buffalo, Buffalo, NY and received his Master’s Degree in Anatomical and Pathological Sciences in 2012. He attended Lake Erie College of Osteopathic Medicine in Erie, Pennsylvania and graduated with his DO in 2016. Dr. Ceretto is currently completing Emergency Medicine Residency at the University of Rochester, Rochester, New York and will become a Fellow of Medical Toxicology at the University of Arizona, Banner Health, Phoenix, Arizona in July of 2019. Dr. Ceretto has special interests in Toxicology and Addiction Medicine. His research interests include understanding trends of the opioid crisis and toxicovigilance of novel psychoactive substances.|
Nels Grauman Neander
|Nels Grauman Neander DO, MASc attended McMaster University and graduated with a Master’s Degree in Chemical Engineering in 2012. He received his DO from Western Health Sciences University in Lebanon, Oregon in 2016. Dr. Grauman Neander is completing Emergency Medicine residency at the University of Rochester, Rochester, New York in June of 2019. He is a certified instructor of the ASAM Buprenorphine course and the FEMA Hospital Emergency Response for Mass Casualty Incidents Course. He is a certified Physician Builder and Analyst for Epic. Dr. Grauman Neander's research interests include Addiction Medicine, Toxicovigilance, Informatics and Disaster Medicine.|
|Sonya Narla DO, MA is a current PGY-3 Family Medicine Resident at the University of Rochester. Dr. Narla attended Case Western Reserve University and graduated with a Bachelor's Degree in English and Master's Degree in Biomedical Ethics in 2011. She then went on to serve as Executive Director of a global health non-profit in West Africa. She recieved her DO from Lake Erie College of Osteopathic Medicine in Erie, PA. She has special interests in global health, underserved health populations, academic family medicine, and optimizing primary care. She has published several articles in Family Doctor, a journal of NYS Academy of Family Physicians, including an article on the Choosing Wisely Guidelines on Controlled Medications in Common Clinical Scenarios.|
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1 AMA PRA Category 1 Credit(s)™ for completing this course.
ABIM Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.